Laser Eye Color Change
Ophthalmology + Aesthetics
Strōma Medical is a pre-revenue, clinical-stage medical device startup with a proprietary laser technology designed to permanently change eye color. Strōma is addressing a significant and rapidly growing market for aesthetic procedures, bypassing the challenges of reimbursement typically associated with medical devices.
Strōma is raising a $15M Series C preferred equity round to fund its pivotal clinical study in Europe and operating expenses.
Clinical data from over 150 procedures
Strong support of key opinion leaders in ophthalmology
Patents issued in 35+ countries
Third-party research showing 1/3 of surveyed express interest in the procedure
Estimated $2.5B annual market opportunity
Contact
Afshin Nadershahi, MD, MBS, MBA
Chief Executive Officer
Strōma Medical Corporation
Irvine, California, USA
Email: afshin@stromamedical.com
Phone: +1.949.783.9562
WhatsApp: 1.310.694.7458
Patient #118
Leadership Team
Afshin Nadershahi, MD, MBS, MBA
Chief Executive Officer
Gregg Homer, JSD (PhD)
Chairman and Chief Science Officer
Tommy J. Harris, CPA, MBA, CGMA
Consulting Chief Financial Officer
Craig Measel, VP Product Commercialization
Michael Orozco, PhD
Senior Director, R&D
Medical Advisory Board
David Huang, MD, PhD
Professor of Ophthalmology, Casey Eye Institute, Oregon Health Sciences University
Ike Ahmed, MD, FRCSC
Professor, Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center
Marguerite McDonald, MD, FACS
Clinical Professor, NYU School of Medicine
Stephen Slade, MD, FACS
Founder and Medical Director, Slade & Baker Vision, Houston, Texas
This summary is for informational purposes only and does not constitute an offer or solicitation to sell shares or securities in Strōma or any related or associated company. Any such offer or solicitation will be made in accordance with the terms of all applicable securities and other laws. None of the information or analyses presented are intended to form the basis for any investment decision, and no specific recommendations are intended. Accordingly, this summary does not constitute investment advice or counsel or solicitation for investment in any security. This summary does not constitute or form part of, and should not be construed as, any offer for sale or subscription of, or any invitation to offer to buy or subscribe for, any securities, nor should it or any part of it form the basis of, or be relied on in any connection with, any contract or commitment whatsoever. Strōma expressly disclaims any and all responsibility for any direct or consequential loss or damage of any kind whatsoever arising directly or indirectly from: (i) reliance on any information contained herein, (ii) any error, omission or inaccuracy in any such information, or (iii) any action resulting therefrom.
© 2024 Strōma Medical Corporation All rights reserved. Strōma and ō are registered trademarks of Strōma Medical Corporation.
The Strōma Laser System is an investigational device, and it is not available for sale or use in the United States.